DUPIXENT® is indicated in patients as young as 6 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.1

DUPIXENT® inhibits the signaling of IL-4 and IL-131†
 

DUPIXENT® binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-13
• IL-4 and IL-13 are key type 2 (including Th2) cytokines involved in atopic disease

DUPIXENT® inhibits IL-4 and IL-13 by specifically binding to IL-4Rα1†

Showing the mechanism of action of DUPIXENT. The image shows a type 1 receptor with IL-4R and γc subunits and a type 2 receptor with IL-4R and IL-13R subunits. Above the receptors is the DUPIXENT monoclonal antibody. IL-4 appears above both receptor types, and IL-13 appears above the type 2 receptor. DUPIXENT inhibits IL-4 and IL-13 signalling by binding to the IL-4R subunit shared by the IL-4 and IL-13 receptor complexes.

Image adapted from Johnston A et al.2
 

IL-4Rα is the common subunit of IL-4 and IL-13 receptor complexes1

† Clinical significance unknown.

DUPIXENT® is not a steroid treatment or an immunosuppressant. DUPIXENT® is an immunomodulator.1


Frequently Asked Questions

Have questions? Get answers to some of the most commonly asked questions.

Dosing and Administration

Thinking about prescribing DUPIXENT®? Find helpful information to get started.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo